Feasibility of a Novel Process-based Treatment for Patients With Psychosis

Summary

The purpose of this single-arm feasibility study is to develop and pilot test a novel process-based and modular group therapy approach for patients with acute psychotic symptoms in an inpatient setting.

Conditions

• Schizophrenia
• Schizotypal Disorder
• Delusional Disorder
• Brief Psychotic Disorder
• Shared Psychotic Disorder
• Schizoaffective Disorder
• Other Psychotic Disorder Not Due to A Substance or Known Physiological Condition
• Unspecified Psychosis Not Due to a Substance or Known Physiological Condition
• Manic Episode, Severe With Psychotic Symptoms
• Bipolar Disorder, Current Episode Manic Severe With Psychotic Features
• Bipolar Disorder, Current Episode Depressed, Severe, With Psychotic Features
• Major Depressive Disorder, Single Episode, Severe With Psychotic Features
• Major Depressive Disorder, Recurrent, Severe With Psychotic Symptoms

Interventions

BEHAVIORAL

Metacognitive and Defusion Training

Module I will give a brief introduction into the rational of the therapy and explain the terms cognitive biases and relational responding and their role in the development of psychological problems (psychosis) in a simple language and with the help of examples and small exercises. The principle of metacognition and cognitive defusion in psychotherapy will be made clear. An outlook on the procedures and the goals of the group therapy will be given. Module II will include interventions adapted from the MCT manual (Moritz et al., 2017) and Module III with consist of defusion strategies taken from the ACT group manual (Dambacher et al., 2020) and existing studies on ACT and psychosis (Bach et al., 2013; Gaudiano \& Herbert, 2006).

Sponsors & Collaborators

• Max-Planck-Institute of Psychiatry

  lead OTHER

Principal Investigators

• Susanne Lucae, MD, Prof. · Max-Planck-Institute of Psychiatry

• Johannes M Kopf-Beck, PhD · Max-Planck-Institute of Psychiatry

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-05-10

Primary Completion

2022-03-10

Completion

2023-09-23

Countries

• Germany

Study Locations